Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Advanced Solid Tumors · Metastatic Solid Tumors · Non-small Cell Lung Cancer (NSCLC) · NSCLC · Colorectal Cancer (CRC) · CRC

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States
Contact: Study coordinator (Spiro Curis) · Scuris@echoct.com · 860-886-8362
Tennessee Oncology, Nashville, Tennessee, United States
Contact: Study coordinator (Kathryn Capps) · Kathryn.capps@thonc.com · 615-879-6410
MD Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Ly Nguyen) · LMNguyen1@mdanderson.org · 832-794-3672
NEXT Dallas, Irving, Texas, United States
Contact: Study coordinator (Mofopefoluwa "Fope" Akinwale) · fakinwale@nextoncology.com · 972-893-8800
NEXT Oncology, San Antonio, Texas, United States
Contact: Study coordinator (Jordan Georg) · jgeorg@nextoncology.com · 210-580-9521
NEXT Virginia, Fairfax, Virginia, United States
Contact: Study coordinator (Maybelle De La Rosa) · mdelarosa@nextoncology.com · 703-783-4518

View source on ClinicalTrials.gov